Accrued Upfront Fee.

No definition available.

Name:	ivvd_AccruedUpfrontFee
Namespace Prefix:	ivvd_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Acquired in-process research and development expense.

+ References

No definition available.

+ Details

Name:	ivvd_AcquiredInProcessResearchAndDevelopmentExpense
Namespace Prefix:	ivvd_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Completion Fee.

+ References

No definition available.

+ Details

Name:	ivvd_CompletionFee
Namespace Prefix:	ivvd_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Delivery Fee.

+ References

No definition available.

+ Details

Name:	ivvd_DeliveryFee
Namespace Prefix:	ivvd_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Exercise Fee.

+ References

No definition available.

+ Details

Name:	ivvd_ExerciseFee
Namespace Prefix:	ivvd_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Milestone payment.

+ References

No definition available.

+ Details

Name:	ivvd_MilestonePayment
Namespace Prefix:	ivvd_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Potential milestone payment.

+ References

No definition available.

+ Details

Name:	ivvd_PotentialMilestonePayment
Namespace Prefix:	ivvd_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Quarterly Fee.

+ References

No definition available.

+ Details

Name:	ivvd_QuarterlyFee
Namespace Prefix:	ivvd_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Research And Developments In Process

+ References

No definition available.

+ Details

Name:	ivvd_ResearchAndDevelopmentsInProcess
Namespace Prefix:	ivvd_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Royalty Based on Net Sales of Licensed Products, Percentage.

+ References

No definition available.

+ Details

Name:	ivvd_RoyaltyBasedOnNetSalesOfLicensedProductsPercentage
Namespace Prefix:	ivvd_
Data Type:	dtr-types:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

Royalty, Percentage of Sublicense Consideration.

+ References

No definition available.

+ Details

Name:	ivvd_RoyaltyPercentageOfSublicenseConsideration
Namespace Prefix:	ivvd_
Data Type:	dtr-types:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

The expenses and losses recorded for each transaction with the acquiree that was recognized separately from the acquisition of assets and assumptions of liabilities in the business combination.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 805
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (e)(3)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479328/805-10-50-2

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 805
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479328/805-10-50-3

+ Details

Name:	us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Total costs of sales and operating expenses for the period.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2

+ Details

Name:	us-gaap_CostsAndExpenses
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-13

+ Details

Name:	us-gaap_PreferredStockSharesIssued
Namespace Prefix:	us-gaap_
Data Type:	xbrli:sharesItemType
Balance Type:	na
Period Type:	instant

- Definition

Amount of expense related to royalty payments under a contractual arrangement such as payment for mineral and drilling rights and use of technology or intellectual property.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(3))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2

+ Details

Name:	us-gaap_RoyaltyExpense
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Details

Name:	us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ivvd_AdimabAssignmentAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_RangeAxis=srt_MaximumMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_RangeAxis=srt_MinimumMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_IncomeStatementLocationAxis=ivvd_AcquiredInProcessResearchAndDevelopmentExpenseMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_ProductOrServiceAxis=ivvd_FirstProductMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_ProductOrServiceAxis=ivvd_SecondProductMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ivvd_AdimabCollaborationAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_ProductOrServiceAxis=ivvd_ResearchDevelopmentAndRegulatoryMilestoneMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ivvd_AdimabPlatformTransferAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ivvd_WuXiCellLineLicenseAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

License and Collaboration Agreements - Additional Information (Details) - USD ($) $ in Thousands			1 Months Ended	3 Months Ended		6 Months Ended		12 Months Ended
	Jan. 01, 2024	Sep. 30, 2022	Jul. 31, 2020	Jun. 30, 2026	Jun. 30, 2025	Jun. 30, 2026	Jun. 30, 2025	Dec. 31, 2023	Dec. 31, 2025	Dec. 31, 2020
Preferred stock, shares issued (in shares)				0		0			0
Acquired IPR&D expense		$ 3,000
Quarterly fee						$ 1,300
Total operating costs and expenses				$ 60,105	$ 26,846	116,985	$ 55,072
Delivery fee						200
Completion fee						200
Exercise fee						$ 1,000
Accrued Upfront Fee										$ 200
Royalty Based on Net Sales of Licensed Products, Percentage						1.00%
Royalty expense						$ 0
Research and Development [Member]
Quarterly fee	$ 600			600	600	1,200	1,200
Adimab Assignment Agreement [Member]
Milestone payment						11,100		$ 11,100
Royalty expense				600	400	$ 1,200	900
Adimab Assignment Agreement [Member] \| Maximum [Member]
Potential milestone payment			$ 24,600
Royalty percentage of sublicense consideration						55.00%
Adimab Assignment Agreement [Member] \| Minimum [Member]
Royalty percentage of sublicense consideration						45.00%
Adimab Assignment Agreement [Member] \| Research and Development [Member]
Recognized expense				0	0	$ 0	0
Adimab Assignment Agreement [Member] \| Acquired In Process Research And Development Expense [Member]
Milestone payment				0	0	0	0
Adimab Assignment Agreement [Member] \| First Product [Member]
Potential milestone payment			16,500
Adimab Assignment Agreement [Member] \| Second Product [Member]
Potential milestone payment			$ 8,100
Adimab Collaboration Agreement [Member]
Total operating costs and expenses				0	0	0	0
Adimab Collaboration Agreement [Member] \| Research and Development [Member]
Quarterly fee				600	600	1,200	1,200
Adimab Collaboration Agreement [Member] \| Acquired In Process Research And Development Expense [Member]
Delivery fee				0	0
Completion fee						0	0
Adimab Collaboration Agreement [Member] \| Research Development And Regulatory Milestone
Potential milestone payment						18,000
Adimab Platform Transfer Agreement [Member]
Research and development expenses				500	500	1,000	1,000
Adimab Platform Transfer Agreement [Member] \| Research Development And Regulatory Milestone
Potential milestone payment						9,500
Cell Line License Agreement [Member]
Acquired IPR&D expense				$ 0	$ 0	$ 0	$ 0